Biohaven (BHVN) to Release Quarterly Earnings on Thursday

Key Points

• Biohaven is expected to release its Q1 2025 earnings results on August 14th, with analysts predicting a loss of ($1.94) per share for the quarter.
• In its previous earnings report, Biohaven missed estimates, reporting ($2.17) per share compared to the expected ($1.67).
• Recent brokerage actions include JPMorgan reducing its target price from $68.00 to $55.00, while Royal Bank of Canada downgraded their rating, cutting the target price from $54.00 to $21.00.

Biohaven (NYSE:BHVN - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Thursday, August 14th. Analysts expect the company to announce earnings of ($1.94) per share for the quarter.

Biohaven (NYSE:BHVN - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($2.17) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.50). On average, analysts expect Biohaven to post $-9 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Biohaven Price Performance

Shares of BHVN stock opened at $15.08 on Thursday. The firm has a fifty day moving average price of $14.68 and a 200-day moving average price of $23.14. Biohaven has a 1 year low of $12.79 and a 1 year high of $55.70. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -1.61 and a beta of 0.98.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BHVN. JPMorgan Chase & Co. dropped their target price on shares of Biohaven from $68.00 to $55.00 and set an "overweight" rating for the company in a research report on Wednesday, June 18th. Royal Bank Of Canada downgraded Biohaven from an "outperform" rating to a "sector perform" rating and cut their target price for the company from $54.00 to $21.00 in a research report on Monday, May 19th. Cantor Fitzgerald raised shares of Biohaven to a "strong-buy" rating in a research report on Tuesday, May 13th. Robert W. Baird decreased their target price on Biohaven from $60.00 to $57.00 and set an "outperform" rating for the company in a research report on Monday, April 28th. Finally, William Blair raised shares of Biohaven to a "strong-buy" rating in a research note on Thursday, April 24th. One research analyst has rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $58.46.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Biohaven by 7.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 589,615 shares of the company's stock worth $14,174,000 after purchasing an additional 41,040 shares during the period. AQR Capital Management LLC grew its position in shares of Biohaven by 49.4% during the first quarter. AQR Capital Management LLC now owns 114,849 shares of the company's stock worth $2,761,000 after buying an additional 37,981 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Biohaven by 32.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,833 shares of the company's stock worth $1,747,000 after buying an additional 17,562 shares during the period. Finally, Intech Investment Management LLC increased its stake in shares of Biohaven by 80.3% during the first quarter. Intech Investment Management LLC now owns 61,598 shares of the company's stock worth $1,481,000 after buying an additional 27,433 shares during the period. Hedge funds and other institutional investors own 88.78% of the company's stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.